OverweightPhase 2NCT07589608
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
A Phase 2 study testing Macupatide and Eloralintide in people with Overweight and Obesity, run by Eli Lilly and Company at 40 sites in United States.
Trial summary
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Overweight, Obesity
- What is being tested?
- Macupatide and Eloralintide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 400 participants
- Where
- 40 sitesUnited States
- Study dates
- 15 May 2026to Feb 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- See Master Protocol CWMM (NCT06143956) for inclusion criteria
Who cannot join
- In addition to exclusion criteria in Master Protocol CWMM (NCT06143956):
- Have type 1 diabetes or type 2 diabetes
- Have an ongoing history of bradyarrhythmia and/or sinus bradycardia
- Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
- Have a history of acute or chronic pancreatitis
- All concomitant medications should be at a stable dose for at least 3 months prior to screening
Trial locations and contacts
40 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
40 sites in 1 country
United States40 sites, 40 recruiting
- Recruiting
Dent Neurologic Institute
Amherst, New York, 14226
Laszlo Mechtler
- Recruiting
Medical Research Partners
Ammon, Idaho, 83406
Joseph Moore
- Recruiting
IMA Clinical Research Austin
Austin, Texas, 78745
Nomita Kim
- Recruiting
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
Chandler, Arizona, 85225
Yessica Sachdeva
- Recruiting
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois, 60640
Rupal Trivedi
- Recruiting
CTI Clinical Research Center
Cincinnati, Ohio, 45212
James Maynard
- Recruiting
StudyMetrix Research
City of Saint Peters, Missouri, 63303
Timothy Smith
- Recruiting
FutureSearch Trials of Dallas
Dallas, Texas, 75251
Michael Downing
- Recruiting
Sovah Clinical Research-River District
Danville, Virginia, 24541
Stephan Jannach
- Recruiting
NorCal Medical Research, Inc
Greenbrae, California, 94904
Linda Gaudiani
- Recruiting
Medication Management
Greensboro, North Carolina, 27401
James Franklin
- Recruiting
Tribe Clinical Research, LLC
Greenville, South Carolina, 29607
Ronald Mayfield
- Recruiting
PlanIt Research, PLLC
Houston, Texas, 77079
Amer Al-Karadsheh
- Recruiting
Velocity Clinical Research, Huntington Park
Huntington Park, California, 90255
Stanley Hsia
- Recruiting
Las Vegas Medical Research
Las Vegas, Nevada, 89128
Cornell Calinescu
- Recruiting
Monroe Biomedical Research - Louisville
Louisville, Kentucky, 40213
Harold Bays
- Recruiting
New Horizon Research Center
Miami, Florida, 33165
Lazaro Nunez
- Recruiting
Indago Research & Health Center, Inc
Miami Lakes, Florida, 33016
Jose Cardona
- Recruiting
Monroe Biomedical Research
Monroe, North Carolina, 28112
Awawu Igbinadolor
- Recruiting
Lucas Research, Inc
Morehead City, North Carolina, 28557
Kathryn Lucas
- Recruiting
Quality Medical Research
Nashville, Tennessee, 37211
Saras Sharma
- Recruiting
Knownwell
Needham, Massachusetts, 02492
Angela Fitch
- Recruiting
Lucida Clinical Trials
New Bedford, Massachusetts, 02740
David Shih
- Recruiting
Lucas Research, Inc.
New Bern, North Carolina, 28562
Joseph Maides
- Recruiting
Suncoast Clinical Research, Inc.
New Port Richey, Florida, 34652
Cathy Barnes
- Recruiting
Charter Research - Winter Park
Orlando, Florida, 32803
Edgardo Rivera-Rivera
- Recruiting
Rochester Clinical Research, LLC
Rochester, New York, 14609
Patrick Connors
- Recruiting
Peninsula Research Associates
Rolling Hills Estates, California, 90274
LeighAnn Schmidt
- Recruiting
Endeavor Clinical Trials
San Antonio, Texas, 78240
Nitendra Agarwal
- Recruiting
Headlands Research - Scottsdale
Scottsdale, Arizona, 85260
Benjamin Clark
- Recruiting
Headlands Research - Detroit
Southfield, Michigan, 48034
Christopher Romero
- Recruiting
Clinvest Headlands Llc
Springfield, Missouri, 65807
Christina Capps
- Recruiting
Stamford Therapeutics Consortium
Stamford, Connecticut, 06905
David Radin
- Recruiting
Charter Research - Lady Lake
The Villages, Florida, 32162
Jeffrey Norton
- Recruiting
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas, 66606
susan brian
- Recruiting
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, 48098
Neil Fraser
- Recruiting
The Institute for Liver Health II dba Arizona Liver Health-Tucson
Tucson, Arizona, 85712
Anita Kohli
- Recruiting
Diablo Clinical Research, Inc.
Walnut Creek, California, 94598
Bonnie Kimmel
- Recruiting
Central Washington Health Services Association d/b/a Confluence Health
Wenatchee, Washington, 98801
Kathryn Eren
- Recruiting
Texas Valley Clinical Research
Weslaco, Texas, 78596
Eduardo Luna
About this study
Official title: A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.
- Conditions
- Overweight, Obesity
- Being tested
- Macupatide, Eloralintide, Placebo
- Medical subject headings
- Overweight, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MacupatideDrug
Also called LY3532226
Administered SC
EloralintideDrug
Also called LY3841136
Administered SC
PlaceboDrug
Administered SC
| Study group | Role | What they receive |
|---|---|---|
| Macupatide Dose 1 | Experimental | Participants will receive macupatide subcutaneously (SC) Receives: Drug: Macupatide |
| Eloralintide Dose 1 | Experimental | Participants will receive eloralintide SC Receives: Drug: Eloralintide |
| Macupatide Dose 1 + Eloralintide Dose 1 | Experimental | Participants will receive macupatide SC and eloralintide SC Receives: Drug: Macupatide; Drug: Eloralintide |
| Eloralintide Dose 2 | Experimental | Participants will receive eloralintide SC Receives: Drug: Eloralintide |
| Macupatide Dose 1 + Eloralintide Dose 2 | Experimental | Participants will receive macupatide SC and eloralintide SC Receives: Drug: Macupatide; Drug: Eloralintide |
| Eloralintide Dose 3 | Experimental | Participants will receive eloralintide SC Receives: Drug: Eloralintide |
| Macupatide Dose 2 + Eloralintide Dose 3 | Experimental | Participants will receive macupatide SC and eloralintide SC Receives: Drug: Macupatide; Drug: Eloralintide |
| Placebo | Placebo comparator | Participants will receive placebo SC Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent Change from Baseline in Body Weight
Measured: Baseline, Week 36
Secondary outcomes (5)
Percent Change from Baseline in Body Weight
Measured: Baseline, Week 48
Change from Baseline in Body Weight
Measured: Baseline, Week 36
Percentage of Participants who Achieve ≥5% Body Weight Reduction
Measured: Week 36
Percentage of Participants who Achieve ≥10% Body Weight Reduction
Measured: Week 36
Change from Baseline in Body Mass Index (BMI)
Measured: Baseline, Week 36
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2026
- Study start15 May 2026
- Primary completionSep 2027 (estimated)
- Study completionFeb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OverweightStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07589608
- Sponsor's protocol ID
- 27844
- Other IDs
- W8M-MC-MC01, W8M-MC-CWMM
- Status last verified
- Oct 2026
- First submitted
- 11 May 2026
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT07589608
- Acronym / sponsor ID
- 27844
- Conditions
- Overweight, Obesity
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- 15 May 2026 (actual)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Feb 2028 (estimated)
- First posted
- 15 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 8
| Arm | Type | Receives |
|---|---|---|
| Macupatide Dose 1 | Experimental | Drug: MacupatideParticipants will receive macupatide subcutaneously (SC) |
| Eloralintide Dose 1 | Experimental | Drug: EloralintideParticipants will receive eloralintide SC |
| Macupatide Dose 1 + Eloralintide Dose 1 | Experimental | Drug: Macupatide, Drug: EloralintideParticipants will receive macupatide SC and eloralintide SC |
| Eloralintide Dose 2 | Experimental | Drug: EloralintideParticipants will receive eloralintide SC |
| Macupatide Dose 1 + Eloralintide Dose 2 | Experimental | Drug: Macupatide, Drug: EloralintideParticipants will receive macupatide SC and eloralintide SC |
| Eloralintide Dose 3 | Experimental | Drug: EloralintideParticipants will receive eloralintide SC |
| Macupatide Dose 2 + Eloralintide Dose 3 | Experimental | Drug: Macupatide, Drug: EloralintideParticipants will receive macupatide SC and eloralintide SC |
| Placebo | Placebo comparator | Drug: PlaceboParticipants will receive placebo SC |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- See Master Protocol CWMM (NCT06143956) for inclusion criteria
Key exclusion criteria (6 listed)
- Have type 1 diabetes or type 2 diabetes
- Have an ongoing history of bradyarrhythmia and/or sinus bradycardia
- Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
- Have a history of acute or chronic pancreatitis
- All concomitant medications should be at a stable dose for at least 3 months prior to screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MacupatideAlso: LY3532226Administered SC | Drug | Macupatide Dose 1, Macupatide Dose 1 + Eloralintide Dose 1, Macupatide Dose 1 + Eloralintide Dose 2, Macupatide Dose 2 + Eloralintide Dose 3 |
| EloralintideAlso: LY3841136Administered SC | Drug | Eloralintide Dose 1, Eloralintide Dose 2, Eloralintide Dose 3, Macupatide Dose 1 + Eloralintide Dose 1, Macupatide Dose 1 + Eloralintide Dose 2, Macupatide Dose 2 + Eloralintide Dose 3 |
| PlaceboAdministered SC | Drug | Placebo |
Primary outcome
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 36
5 secondary outcomes
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 48
Change from Baseline in Body Weight
Time frame: Baseline, Week 36
Percentage of Participants who Achieve ≥5% Body Weight Reduction
Time frame: Week 36
Percentage of Participants who Achieve ≥10% Body Weight Reduction
Time frame: Week 36
Change from Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 36
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- A clinical trial for adults living with obesity or overweight and without diabetesLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Related trials for Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
40 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Macupatide and Eloralintide in people with Overweight and Obesity, run by Eli Lilly and Company at 40 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 40 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or (317-615-4559, LillyTrials@Lilly.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent Change from Baseline in Body Weight (time frame: Baseline, Week 36). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.